Cocrystal Pharma Announces Presentation at the RespiDART 2018: Frontiers in Drug Development Against Respiratory Viruses Conf...
01 December 2018 - 12:00AM
- Proprietary technology has the ability to fuel
Cocrystal’s pipeline by effectively creating small molecule
antiviral therapeutics that are safe, effective, convenient to
administer and have the potential to address high-value areas of
unmet medical needs -
Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the
“Company”), a clinical stage biotechnology company discovering and
developing novel antiviral therapeutics that target the
replication machinery of hepatitis viruses, influenza viruses
and noroviruses, announced today that Sam Lee, Ph.D.,
President of Cocrystal, presented at the RespiDART 2018: Frontiers
in Drug Development Against Respiratory Viruses Conference being
held November 29 - 30, 2018 in Miami, Florida.
As part of Dr. Lee’s oral presentation, he
discussed the Company’s proprietary platform technology and its
influenza drug pipeline design. Cocrystal’s technology utilizes
proprietary structural information, enzymology, and chemistry
expertise, enabling the Company to develop novel antiviral agents.
These technologies and Cocrystal’s market-focused approach to drug
discovery are designed to effectively create small molecule
therapeutics that are safe, effective and convenient to
administer.
“Our unique structure-based platform technology
has continued to demonstrate its potential in the development of
antivirals. While we continue to leverage our technology in our
current development programs for HepC, influenza, and noroviruses,
we believe our platform has the potential to fuel a diverse
pipeline that will have a meaningful impact on a number of
high-value indications,” commented Dr. Lee. “By utilizing our
platform technology in our CC-42344 influenza program, we have
developed molecules with the ability to target the influenza
polymerase complex, an essential replication enzyme with several
highly conserved regions common to all influenza strains. CC-42344
has shown excellent antiviral activity against influenza A strains,
including avian pandemic strains and Tamiflu® resistant strains.
The data we have seen in this program to date continues to be
encouraging and we look forward to providing additional
updates.”
Cocrystal is applying its proprietary platform
technology to develop novel, broad spectrum influenza antivirals
that are specifically designed to be effective against all
significant A strains of the influenza virus and to have a high
barrier to resistance due to the way they target the virus’s
replication machinery. CC-42344, the Company’s lead molecule for
the treatment of influenza, binds to a highly conserved PB2 site on
the influenza polymerase complex and exhibits a novel mechanism of
action that inhibits viral replication. CC-42344 has shown
excellent antiviral activity against influenza A strains, including
avian pandemic strains and Tamiflu® resistant strains, and shows a
favorable pharmacokinetic and safety profile. CC-42344 is currently
being evaluated in preclinical IND-enabling studies for the
treatment of influenza.
About RespiDART 2018
By bringing together world leaders and key
opinion holders, RespiDART 2018 will address the latest challenges
in vaccine and drug development against respiratory viruses.
Through rigorous discussions, data sharing, and community building,
this meeting aims to identify major clinical and scientific
roadblocks, thus paving the way for game-changing scientific
advancement.
RespiDART 2018 will focus on topics such as
epidemiology and diagnosis, virus-host interactions and virus
enzymology, vaccine and immunology, small molecule development,
drug resistance and virus evolution. Emphasis will be placed on
sharing the latest clinical data for several small molecules
currently being tested in humans. Novel drug targets and mechanisms
of action will also be heavily explored. Ultimately, “RespiDART
2018” aims to bridge the gap between the latest scientific
developments and real-world clinical needs. Medical progress
against respiratory viruses has been advancing at an inspiring
rate. For more information about the conference, please visit the
conference website.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical stage biotechnology company
discovering and developing novel antiviral therapeutics that target
the replication machinery of hepatitis C viruses, influenza
viruses, and noroviruses. Cocrystal employs unique structure-based
technologies and Nobel Prize winning expertise to create first- and
best-in-class antiviral drugs. CC-31244 is a broad-spectrum novel
non-nucleoside replication inhibitor of the hepatitis C virus.
Phase 1b studies in HCV-infected patients showed the largest
reduction in viral load of any non-nucleoside inhibitor tested to
date. CC-31244 is now in a Phase 2a clinical trial as part of a
cocktail for the ultra-short therapy of 6 weeks. The Company’s lead
candidate CC-42344 for influenza is effective in animal models
against both the pandemic and seasonal strains of influenza A. In
addition, novel inhibitors effective against both influenza strains
A and B have been identified and are in the preclinical stage.
Several of these inhibitors have potencies approaching single digit
nanomolar. We continue to identify and develop non-nucleoside
polymerase inhibitors for Norovirus infections using the Company’s
proprietary structure-based drug design technology platform. For
further information about Cocrystal, please visit
www.cocrystalpharma.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995, including the prospects for the Company’s
influenza lead candidate. The words "believe," "may," "estimate,"
"continue," "anticipate," "intend," "should," "plan," "could,"
"target," "potential," "is likely," "will," "expect" and similar
expressions, as they relate to us, are intended to identify
forward-looking statements. We have based these forward-looking
statements largely on our current expectations and projections
about future events. Some or all of the events anticipated by these
forward-looking statements may not occur. Important factors that
could cause actual results to differ from those in the
forward-looking statements include the continued preclinical
research developments, the ultimate results of a Phase 1 clinical
trial and later stage clinical trials, the availability of products
manufactured by third parties and receipt of regulatory approvals.
Further information on our risk factors is contained in our filings
with the SEC, including our Quarterly Report on Form 10-Q for the
quarter ended September 30, 2018, the Prospectus Supplement dated
July 19, 2018, and our Annual Report on Form 10-K for the year
ended December 31, 2017. Any forward-looking statement made by us
herein speaks only as of the date on which it is made. Factors or
events that could cause our actual results to differ may emerge
from time to time, and it is not possible for us to predict all of
them. We undertake no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by
law.
Investor and Media
Contact:Jenene Thomas Communications, LLC(833)
475-8247COCP@jtcir.com
###
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Apr 2024 to May 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From May 2023 to May 2024